Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/22595
Title: Cardiac atrial appendage stem cells promote angiogenesis in vitro and in vivo
Authors: FANTON, Yanick 
Houbrechts, Cynthia
WILLEMS, Leen 
Daniëls, Annick
LINSEN, Loes 
RATAJCZAK, Jessica 
BRONCKAERS, Annelies 
LAMBRICHTS, Ivo 
DECLERCQ, Jeroen 
RUMMENS, Jean-Luc 
HENDRIKX, Marc 
HENSEN, Karen 
Issue Date: 2016
Publisher: ELSEVIER SCI LTD
Source: JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 97, p. 235-244
Abstract: Cardiac atrial appendage stem cells (CASCs) show extraordinary myocardial differentiation properties, making them ideal candidates for myocardial regeneration. However, since the myocardium is a highly vascularized tissue, revascularization of the ischemic infarct area is essential for functional repair. Therefore, this study assessed if CASCs contribute to cardiac angiogenesis via paracrine mechanisms. First, it was demonstrated that CASCs produce and secrete high levels of numerous angiogenic growth factors, including vascular endothelial growth factor (VEGF), endothelin-1 (ET-1) and insulin-like growth factor binding protein 3 (IGFBP-3). Functional in vitro assays with a human microvascular endothelial cell line (HMEC-1) and CASC CM showed that CASCs promote endothelial cell proliferation, migration and tube formation, the most important steps of the angiogenesis process. Addition of inhibitory antibodies against identified growth factors could significantly reduce these effects, indicating their importance in CASC-induced neovascularization. The angiogenic potential of CASCs and CASC CM was also confirmed in a chorioallantoic membrane assay, demonstrating that CASCs promote blood vessel formation in vivo. In conclusion, this study shows that CASCs not only induce myocardial repair by cardiomyogenic differentiation, but also stimulate blood vessel formation by paracrine mechanisms. The angiogenic properties of CASCs further strengthen their therapeutic potential and make them an optimal stem cell source for the treatment of ischemic heart disease.
Notes: [Fanton, Yanick; Willems, Leen; Daniels, Annick; Declercq, Jeroen; Rummens, Jean-Luc; Hensen, Karen] Jessa Hosp, Lab Expt Hematol, Hasselt, Belgium. [Fanton, Yanick; Houbrechts, Cynthia; Willems, Leen; Declercq, Jeroen; Rummens, Jean-Luc; Hendrikx, Marc; Hensen, Karen] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium. [Linsen, Loes] Univ Hosp Leuven, AC Biobanking, Leuven, Belgium. [Ratajczak, Jessica; Bronckaers, Annelies; Lambrichts, Ivo] Hasselt Univ, Biomed Res Inst, Hasselt, Belgium. [Hendrikx, Marc] Jessa Hosp, Dept Cardiothorac Surg, Hasselt, Belgium.
Keywords: angiogenesis; growth factors and cytokines; stem cell; cardiac progenitor cells; endothelial cell;Angiogenesis; Growth factors and cytokines; Stem cell; Cardiac progenitor cells; Endothelial cell
Document URI: http://hdl.handle.net/1942/22595
ISSN: 0022-2828
e-ISSN: 1095-8584
DOI: 10.1016/j.yjmcc.2016.06.005
ISI #: 000382800100026
Rights: (C) 2016 Elsevier Ltd. All rights reserved.
Category: A1
Type: Journal Contribution
Validations: ecoom 2017
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
fanton 1.pdf
  Restricted Access
Published version2.24 MBAdobe PDFView/Open    Request a copy
Cardiac.pdfPeer-reviewed author version1.1 MBAdobe PDFView/Open
Show full item record

SCOPUSTM   
Citations

11
checked on Sep 3, 2020

WEB OF SCIENCETM
Citations

18
checked on Mar 29, 2024

Page view(s)

140
checked on Jun 14, 2022

Download(s)

378
checked on Jun 14, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.